Pleiotropic Effects of PCSK9 Inhibitors on Cardio-Cerebrovascular Diseases
Zhenzhen Li, Lin Zhu, Yeqiong Xu, Yiting Zhang, Yukai Liu, Huiling Sun, Shuo Li, Meng Wang, Teng Jiang, Junshan Zhou, Qiwen Deng · 2024
Read Pleiotropic Effects of PCSK9 Inhibitors on Cardio-Cerebrovascular Diseases by Zhenzhen Li, Lin Zhu, Yeqiong Xu, Yiting Zhang, Yukai Liu, Huiling Sun, Shuo Li, Meng Wang, Teng Jiang, Junshan Zhou, Qiwen Deng (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11726846.txt.
Description
Zhenzhen Li and ten co-authors review the wider effects of PCSK9 inhibitor drugs on heart and brain vessel disease, in a 2024 survey. The drugs were built to cut bad cholesterol, a main driver of heart attacks and strokes. They work by blocking a protein that would otherwise destroy the cell gates that pull cholesterol from the blood. With more gates left standing, blood levels fall sharply, beyond what statins alone achieve.
Trials show the drugs plus statins improve outcomes for heart patients and for stroke patients with narrowed brain arteries. The review also gathers proof of side benefits: less vessel inflammation, steadier plaques, and less clot formation. The authors sort the proof by organ system, heart first and brain second. They frame the drugs as multi-use tools, not just cholesterol cutters.
Catalog record
| CREATOR | Zhenzhen Li, Lin Zhu, Yeqiong Xu, Yiting Zhang, Yukai Liu, Huiling Sun, Shuo Li, Meng Wang, Teng Jiang, Junshan Zhou, Qiwen Deng |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |